The role of cytokines and growth factors in fibroproliferative lung disease;Die bedeutung von zytokinen und wachstumsfaktoren bei fibrosierenden lungenerkrankungen

Pneumologie

Volumn 57, Issue 2, 2003, Pages 91-97

  Kolb, M ^a   Schmidt, M ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; FIBROBLAST GROWTH FACTOR; GAMMA INTERFERON; GROWTH FACTOR; INTERLEUKIN 1; PIRFENIDONE; PLATELET DERIVED GROWTH FACTOR; RELAXIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

LUNG FIBROSIS; PATHOGENESIS; PNEUMONIA; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; WOUND HEALING;

CYTOKINES; GROWTH SUBSTANCES; HUMANS; INFLAMMATION; PULMONARY FIBROSIS; WOUND HEALING;

EID: 0037325489     PISSN: 09348387     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-37153     Document Type: Review

References (74)

1. Lympany PA, du Bois RM. Diffuse lung disease: product of genetic susceptibility and environmental encounters. Thorax 1997; 52: 92-94
2. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med 2001; 345: 517-525
3. Ryu JH, Colby TV, Hartman TE. Idiopathic pulmonary fibrosis: current concepts. Mayo Clin Proc 1998; 73: 1085-1101
4. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161: 646-664
5. Selman M, King TE, Pardo A. Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and Implications for Therapy. Ann Intern Med 2001; 134: 136-151
6. Sime PJ, Gauldie J. Mechanisms of scarring. In: Evans TWHC (editor). ARDS in adults. London: Chapman & Hall Medical, 1996: 215-231
7. Sheppard D. Pulmonary fibrosis: a cellular overreaction or a failure of communication? J Clin Invest 2001; 107: 1501-1502
8. Gauldie J, Kolb M, Sime PJ. A new direction in the pathogenesis of idiopathic pulmonary fibrosis? Respir Res 2002; 3: 1
9. Lasky JA, Brody AR. Interstitial fibrosis and growth factors. Environ Health Perspect 2000; 108 Suppl 4: 751-762
10. Allen JT, Spiteri MA. Growth factors in idiopathic pulmonary fibrosis: relative roles. Respir Res 2002; 3: 13
11. Kunkel SL, Chemotactic cytokines: the chemokine family. In: Phan S (editor). Pulmonary fibrosis. New York: Marcel Dekker, 1995: 579-597
12. Gauldie J, Sime PJ, Xing Z et al. Transforming growth factor-beta gene transfer to the lung induces myofibroblast presence and pulmonary fibrosis. Curr Top Pathol 1999; 93: 35-45
13. Remick D. Cytokines and pulmonary fibrosis. In: Pulmonary fibrosis. New York: Marcel Dekker, 1995: 599-626
14. Khalil N, O'Connor RN. Cytokine regulation of pulmonary fibrosis: TGFbeta. In: Pulmonary fibrosis. New York: Marcel Dekker, 1995: 627-645
15. Keane MP, Strieter RM. The importance of balanced pro-inflammatory and anti-inflammatory mechanisms in diffuse lung disease. Respir Res 2002; 3: 5
16. Ward PA, Hunninghake GW. Lung inflammation and fibrosis. Am J Respir Crit Care Med 1998; 157: S123-S129
17. Dinarello CA. Interleukin-1. Cytokine Growth Factor Rev 1997; 8: 253-265
18. Rochester CL, Elias JA. Cytokines and cytokine networking in the pathogenesis in interstitial and fibrotic lung disorders. Semir Respir Crit Care Med 1994; 14: 389-416
19. Boyle JE, Lindroos PM, Rice AB et al. Prostaglandin-E2 counteracts interleukin-1beta-stimulated upregulation of platelet-derived growth factor alpha-receptor on rat pulmonary myofibroblasts. Am J Respir Cell Mol Biol 1999; 20: 433-440
20. Phan SH, Kunkel SL. Lung cytokine production in bleomycin-induced pulmonary fibrosis. Exp Lung Res 1992; 18: 29-43
21. Thrall RS, Scalise PJ. Bleomycin. In: Phan SH (editor). Pulmonary Fibrosis. New York: Marcel Dekker, 1995: 231-292
22. Pan LH, Ohtani H, Yamauchi K et al. Co-expression of TNF alpha and IL-1 beta in human acute pulmonary fibrotic diseases: an immunohistochemical analysis. Pathol Int 1996; 46: 91-99
23. Johnston CJ, Piedboeuf B, Rubin P et al. Early and persistent alterations in the expression of interleukin-1 alpha, interleukin-1 beta and tumor necrosis factor alpha mRNA levels in fibrosis-resistant and sensitive mice after thoracic irradiation. Radiat Res 1996; 145: 762-767
24. Lee YM, Hybertson BM, Cho HG et al. Platelet-activating factor contributes to acute lung leak in rats given interleukin-1 intratracheally. Am J Physiol Lung Cell Mol Physiol 2000; 279: L75-L80
25. Hybertson BM, Lee YM, Repine JE. Phagocytes and acute lung injury: dual roles for interleukin-1. Ann NY Acad Sci 1997; 832: 266-273
26. Kolb M, Margetts PJ, Anthony DC et al. Transient expression of IL-1 beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. J Clin Invest 2001; 107: 1529-1536
27. Kotecha S, Wilson L, Wangoo A et al. Increase in interleukin (IL)-1 beta and IL-6 in bronchoalveolar lavage fluid obtained from infants with chronic lung disease of prematurity. Pediatr Res 1996; 40: 250-256
28. Sporn MB, Roberts AB. Peptide growth factors and their receptors. New York: Springer, 1991
29. Tufvesson E, Westergren-Thorsson G. Alteration of proteoglycan synthesis in human lung fibroblasts induced by interleukin-1beta and tumor necrosis factor-alpha. J Cell Biochem 2000; 77: 298-309
30. Ortiz LA, Lasky J, Hamilton Jr RF et al. Expression of TNF and the necessity of TNF receptors in bleomycin-induced lung injury in mice. Exp Lung Res 1998; 24: 721-743
31. Sime PJ, Marr RA, Gauldie D et al. Transfer of tumor necrosis factor-alpha to rat lung induces severe pulmonary inflammation and patchy interstitial fibrogenesis with induction of transforming growth factor-beta1 and myofibroblasts. Am J Pathol 1998; 153: 825-832
32. Ziegenhagen MW, Schrum S, Zissel G et al. Increased expression of proinflammatory chemokines in bronchoalveolar lavage cells of patients with progressing idiopathic pulmonary fibrosis and sarcoidosis. J Investig Med 1998; 46: 223-231
33. O'Kane S, Ferguson MW. Transforming growth factor beta s and wound healing. Int J Biochem Cell Biol 1997; 29: 63-78
34. Letterio JJ, Roberts AB. TGF-beta: a critical modulator of immune cell function. Clin Immunol Immunopathol 1997; 84: 244-250
35. Munger JS, Huang X, Kawakatsu H et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999; 96: 319-328
36. Fish JE, Peters SP. Airway remodeling and persistent airway obstruction in asthma. J Allergy Clin Immunol 1999; 104: 509-516
37. Mutsaers SE, Bishop JE, McGrouther G et al. Mechanisms of tissue repair: from wound healing to fibrosis. Int J Biochem Cell Biol 1997; 29: 5-17
38. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994; 331: 1286-1292
39. Rubin P, Johnston CJ, Williams JP et al. A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis [see comments]. Int J Radiat Oncol Biol Phys 1995; 33: 99-109
40. Sime PJ, Xing Z, Graham FL et al. Adenovector-mediated gene transfer of active transforming growth factor- beta1 induces prolonged severe fibrosis in rat lung. J Clin Invest 1997; 100: 768-776
41. Anscher MS, Kong FM, Andrews K et al. Plasma transforming growth factor beta1 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys 1998; 41: 1029-1035
42. Fabisiak JP, Kelley J. Platelet derived growth factor. In: Kelley J (editor). Cytokines of the lung. New York: Marcel Dekker, 1993: 3-39
43. Rice AB, Moomaw CR, Morgan DL et al. Specific inhibitors of platelet-derived growth factor or epidermal growth factor receptor tyrosine kinase reduce pulmonary fibrosis in rats. Am J Pathol 1999; 155: 213-221
44. Lasky JA, Tonthat B, Liu JY et al. Upregulation of the PDGF-alpha receptor precedes asbestos-induced lung fibrosis in rats. Am J Respir Crit Care Med 1998; 157: 1652-1657
45. Bostrom H, Willetts K, Pekny M et al. PDGF-A signaling is a critical event in lung alveolar myofibroblast development and alveogenesis. Cell 1996; 85: 863-873
46. Chung KF, Barnes PJ. Cytokines in asthma. Thorax 1999; 54: 825-857
47. Barrios R, Pardo A, Ramos C et al. Upregulation of acidic fibroblast growth factor during development of experimental lung fibrosis. Am J Physiol 1997; 273: L451-L458
48. Liebler JM, Picou MA, Qu Z et al. Altered immunohistochemical localization of basic fibroblast growth factor after bleomycin-induced lung injury. Growth Factors 1997; 14: 25-38
49. Kadono T, Kikuchi K, Kubo M et al. Serum concentrations of basic fibroblast growth factor in collagen diseases. J Am Acad Dermatol 1996; 35: 392-397
50. Stern JB, Fierobe L, Paugam C et al. Keratinocyte growth factor and hepatocyte growth factor in bronchoalveolar lavage fluid in acute respiratory distress syndrome patients. Crit Care Med 2000; 28: 2326-2333
51. Anscher MS, Peters WP, Reisenbichler H et al. Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N Engl J Med 1993; 328: 1592-1598
52. Vogel E, Kolb M, Mueller J et al. BAL levels of the profibrotic cytokines TGFbeta and PDGF in patients with interstitial lung disease. Eur Respir J 2000; 14: 369S
53. Piguet PF, Vesin C. Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. Eur Respir J 1994; 7: 515-518
54. Piguet PF, Vesin C, Grau GE et al. Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica. Cytokine 1993; 5: 57-61
55. Entzian P, Zahringer U, Schlaak M et al. Comparative study on effects of pentoxifylline, prednisolone and colchicine in experimental alveolitis. Int J Immunopharmacol 1998; 20: 723-735
56. Zabel P, Entzian P, Dalhoff K et al. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med 1997; 155: 1665-1669
57. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999; 291: 367-373
58. van den Berg WB. Anti-cytokine therapy in chronic destructive arthritis. Arthritis Res 2001; 3: 18-26
59. Wang Q, Wang Y, Hyde DM et al. Reduction of bleomycin induced lung fibrosis by transforming growth factor beta soluble receptor in hamsters. Thorax 1999; 54: 805-812
60. Giri SN, Hyde DM, Braun RK et al. Antifibrotic effect of decorin in a bleomycin hamster model of lung fibrosis. Biochem Pharmacol 1997; 54: 1205-1216
61. Giri SN, Hyde DM, Hollinger MA. Effect of antibody to transforming growth factor beta on bleomycin induced accumulation of lung collagen in mice. Thorax 1993; 48: 959-966
62. Kolb M, Margetts PJ, Galt T et al. Transient Transgene Expression of Decorin in the Lung Reduces the Fibrotic Response to Bleomycin. Am J Respir Crit Care Med 2001; 163: 770-777
63. Molteni A, Moulder JE, Cohen EF et al. Control of radiation-induced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensin II type 1 receptor blocker. Int J Radiat Biol 2000; 76: 523-532
64. Gurujeyalakshmi G, Hollinger MA, Giri SN. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am J Physiol 1999; 276: L311-L318
65. Gurujeyalakshmi G, Hollinger MA, Giri SN. Regulation of transforming growth factor-beta1 mRNA expression by taurine and niacin in the bleomycin hamster model of lung fibrosis. Am J Respir Cell Mol Biol 1998; 18: 334-342
66. Ziesche R, Hofbauer E, Wittmann K et al. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999; 341: 1264-1269
67. Franklin TJ. Therapeutic approaches to organ fibrosis. Int J Biochem Cell Biol 1997; 29: 79-89
68. Marshall RP, McAnulty RJ, Laurent GJ. Angiotensin II is mitogenic for human lung fibroblasts via activation of the type 1 receptor. Am J Respit Crit Care Med 2000; 161: 1999-2004
69. Yoshida M, Sakuma-Mochizuki J, Abe K et al. In vivo gene transfer of an extracellular domain of platelet-derived growth factor beta receptor by the HVJ-liposome method ameliorates bleomycin-induced pulmonary fibrosis. Biochem Biophys Res Commun 1999; 265: 503-508
70. Bienkowski RS, Gotkin MG. Control of collagen deposition in mammalian lung. Proc Soc Exp Biol Med 1995; 209: 118-140
71. Gurujeyalakshmi G, Giri SN. Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-beta and procollagen I and III gene expression. Exp Lung Res 1995; 21: 791-808
72. Raghu G, Johnson WC, Lockhart D et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med 1999; 159: 1061-1069
73. Unemori EN, Pickford LB, Salles AL et al. Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo. J Clin Invest 1996; 98: 2739-2745
74. Seibold JR, Korn JH, Simms R et al. Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000; 132: 871-879